Stock Scorecard

Stock Summary for Biogen Inc (BIIB) - $126.54 as of 6/19/2025 2:06:38 PM EST

Total Score

14 out of 30

Safety Score

68 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for BIIB

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BIIB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BIIB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BIIB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BIIB (68 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 2
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BIIB

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen ( NASDAQ:BIIB ) 6/18/2025 11:30:00 AM
What Does the Market Think About Biogen? - Biogen ( NASDAQ:BIIB ) 6/17/2025 8:00:00 PM
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal 6/17/2025 6:36:00 PM
Virtualware will uplist on Euronext Growth Paris on June 19, following market approval 6/17/2025 5:55:00 AM
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal - Sage Therapeutics ( NASDAQ:SAGE ) , Biogen ( NASDAQ:BIIB ) 6/16/2025 1:45:00 PM
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE ) 6/16/2025 11:00:00 AM
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio 6/16/2025 11:00:00 AM
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results - Biogen ( NASDAQ:BIIB ) 6/12/2025 3:33:00 PM
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology ( EULAR ) Show Improvement in Fatigue and Reduction in Disease Activity 6/12/2025 5:00:00 AM
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments 6/9/2025 8:05:00 PM

Financial Details for BIIB

Company Overview
Ticker BIIB
Company Name Biogen Inc
Country USA
Description Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 3/31/2025
Next Earnings Date 7/30/2025

Stock Price History
Last Day Price 126.54
Price 4 Years Ago 239.92
Last Day Price Updated 6/19/2025 2:06:38 PM EST
Last Day Volume 2,331,174
Average Daily Volume 1,616,139
52-Week High 238.00
52-Week Low 110.04
Last Price to 52 Week Low 14.99%

Valuation Measures
Trailing PE 12.50
Industry PE 60.81
Sector PE 40.43
5-Year Average PE 19.85
Free Cash Flow Ratio 7.14
Industry Free Cash Flow Ratio 19.08
Sector Free Cash Flow Ratio 31.51
Current Ratio Most Recent Quarter 1.44
Total Cash Per Share 17.73
Book Value Per Share Most Recent Quarter 115.90
Price to Book Ratio 1.09
Industry Price to Book Ratio 18.89
Sector Price to Book Ratio 30.07
Price to Sales Ratio Twelve Trailing Months 1.89
Industry Price to Sales Ratio Twelve Trailing Months 46.69
Sector Price to Sales Ratio Twelve Trailing Months 34.41
Analyst Buy Ratings 13
Analyst Strong Buy Ratings 5

Share Statistics
Total Shares Outstanding 146,528,000
Market Capitalization 18,541,653,120
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.71%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY -39.30%
Annual Earnings Growth 40.57%
Reported EPS 12 Trailing Months 10.12
Reported EPS Past Year 3.02
Reported EPS Prior Year 16.47
Net Income Twelve Trailing Months 1,479,300,000
Net Income Past Year 1,632,200,000
Net Income Prior Year 1,161,100,000
Quarterly Revenue Growth YOY 6.10%
5-Year Revenue Growth -7.62%
Operating Margin Twelve Trailing Months 28.10%

Balance Sheet
Total Cash Most Recent Quarter 2,598,300,000
Total Cash Past Year 2,375,000,000
Total Cash Prior Year 1,049,900,000
Net Cash Position Most Recent Quarter -1,950,400,000
Net Cash Position Past Year -2,172,200,000
Long Term Debt Past Year 4,547,200,000
Long Term Debt Prior Year 6,788,200,000
Total Debt Most Recent Quarter 4,548,700,000
Equity to Debt Ratio Past Year 0.79
Equity to Debt Ratio Most Recent Quarter 0.79
Total Stockholder Equity Past Year 16,716,000,000
Total Stockholder Equity Prior Year 14,799,400,000
Total Stockholder Equity Most Recent Quarter 16,978,700,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 2,295,600,000
Free Cash Flow Per Share Twelve Trailing Months 15.67
Free Cash Flow Past Year 2,515,700,000
Free Cash Flow Prior Year 1,235,800,000

Options
Put/Call Ratio 0.64
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 1.50
MACD Signal 2.08
20-Day Bollinger Lower Band 111.66
20-Day Bollinger Middle Band 130.89
20-Day Bollinger Upper Band 150.11
Beta 0.15
RSI 45.67
50-Day SMA 162.14
150-Day SMA 224.78
200-Day SMA 227.72

System
Modified 6/19/2025 7:00:46 PM EST